Health Care • Other Pharmaceuticals
$2.93 ▼ -0.01
(-0.34%)
MKT CAP: $63.9M • VOL: 79.4K
52W L $1 52W H $15
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
ZSTK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $35.7M | $35.9M | $76.1M |
| YoY Revenue Growth % | -0.5% | -52.9% | — |
| Gross Profit | $1.6M | $2.2M | — |
| Gross Margin % | 4.6% | 6.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$154.7M | -$8.9M | -$50.4M |
| Operating Margin % | -80.0% | -24.9% | -66.2% |
| Net Income (GAAP) | $0 | -$15.9M | -$57.0M |
| EBITDA (Normalized) | -$154.6M | -$8.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.7M | -$5.0M | -$8.4M |
| Capital Expenditures (CapEx) | $127.0K | $134.0K | — |
| Free Cash Flow (FCF) | -$8.8M | -$5.2M | -$8.4M |
| FCF Margin % | -24.7% | -14.4% | -11.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.6M | $5.2M | — |
| Total Debt (Short + Long Term) | $50.8M | $0 | — |
| Total Stockholders' Equity | $70.6M | $4.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZSTK.